Patent intelligence · US
US 6723855
Method for synthesizing leflunomide
Method for synthesizing leflunomide
Patent details — US 6723855
- Jurisdiction
- US
- Status
- expired
- Grant date
- Apr 20, 2004
- Expiration
- Apr 15, 2024
- Applicant
- TEVA PHARMACEUTICAL INDUSTRIES, LTD.
- Claims
- 26
- CPC classes
- A61K, A61K31/42, A61P, A61P11/02
Quick answer
US 6723855 (Method for synthesizing leflunomide) is held by TEVA PHARMACEUTICAL INDUSTRIES, LTD.. Status: expired. Granted Apr 20, 2004. Expires Apr 15, 2024 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- TEVA PHARMACEUTICAL INDUSTRIES, LTD.
- Grant date
- Expiration
- Claims
- 26
- CPC classes
- A61K, A61K31/42, A61P, A61P11/02, A61P11/06, A61P17/06
More from TEVA PHARMACEUTICAL INDUSTRIES, LTD.
Related pharmaceutical patents in our USPTO index.
-
US 12310929
Use of rasagiline for the treatment of restless legs syndrome
granted -
US 12258401
Anti-CD47 combination therapy
granted -
US 12157729
Solid state forms of Belumosudil and Belumosudil salts
granted -
US 12139528
Treating refractory migraine
granted -
US 12091388
Solid state forms of Reproxalap
granted -
US 11826322
Pre-filled syringe
granted -
US 11813359
Sustained release olanzapine formulations
granted -
US 11773083
Solid state forms of Belumosudil and Belumosudil salts
granted
Frequently asked questions
What is US patent 6723855?
US 6723855 (Method for synthesizing leflunomide) is held by TEVA PHARMACEUTICAL INDUSTRIES, LTD.. Status: expired. Granted Apr 20, 2004. Expires Apr 15, 2024 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6723855?
TEVA PHARMACEUTICAL INDUSTRIES, LTD. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 454 pharmaceutical patents for this assignee.
When does US 6723855 expire?
Our index shows an expiration date of Apr 15, 2024 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.